JPS63500517A - Medicinal hair loss prevention complex compounds and compositions - Google Patents

Medicinal hair loss prevention complex compounds and compositions

Info

Publication number
JPS63500517A
JPS63500517A JP61503578A JP50357886A JPS63500517A JP S63500517 A JPS63500517 A JP S63500517A JP 61503578 A JP61503578 A JP 61503578A JP 50357886 A JP50357886 A JP 50357886A JP S63500517 A JPS63500517 A JP S63500517A
Authority
JP
Japan
Prior art keywords
polymer
derivative
glycol
surfactant
complex compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61503578A
Other languages
Japanese (ja)
Inventor
ダーコ，ラズロ　エル
Original Assignee
フア−マコン，インコ−ポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フア−マコン，インコ−ポレイテツド filed Critical フア−マコン，インコ−ポレイテツド
Publication of JPS63500517A publication Critical patent/JPS63500517A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups

Abstract

(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 薬用脱毛防止錯化合物および組成物 本出願は人体頭皮の脱毛防止に有用な、薬用として活性な錯化合物に関するもの である。よシ詳細に言うならば、それはアリルイソチオシアネートと成る種のポ リオキシアルキレングリコールとの反応によって生成した錯化合物、このような 錯化合物を含む薬用組成物および人の脱毛防止を目的とする錯化合物の使用に関 するものでポリオキシアルキレングリコールは公知の界面活性剤ポリマー群であ る。それらは選択されたグリコールの重合によって形成されるエーテルである。[Detailed description of the invention] Medicinal hair loss prevention complex compounds and compositions This application relates to medicinally active complex compounds useful for preventing hair loss on the human scalp. It is. To be more specific, it is a species of allyl isothiocyanate. Complex compounds formed by reaction with lyoxyalkylene glycol, such Regarding medicinal compositions containing complex compounds and the use of complex compounds for the purpose of preventing hair loss in humans. Polyoxyalkylene glycol is a well-known group of surfactant polymers. Ru. They are ethers formed by polymerization of selected glycols.

それらは種々の形で得られる。それらはしばしば他の官能基を有する。They are available in various forms. They often have other functional groups.

本発明の実地に有用な界面活性剤ポリマーは５００〜１０．０００の分子量をも ち、アルキレン基は２または３箇の炭素原子を有する。本発明の実地に有用な特 殊な界面活性剤ポリマーには、アルキレン基に２ｔたは３箇の炭素原子を有する グリコールから誘導される共重合体が含まれる。Surfactant polymers useful in the practice of this invention also have molecular weights between 500 and 10,000. In other words, the alkylene group has 2 or 3 carbon atoms. Features useful in practice of the invention Special surfactant polymers have 2t or 3 carbon atoms in the alkylene group. Included are copolymers derived from glycols.

本発明に有用な界面活性剤ポリマーの１群はＢＡＳＦ　−ワイアンドット社（Ｂ ＡＳＦ　−Ｗｙａｎｄｏｔｔｅ　）から、プルＣｌニック（Ｐｌｕｒｏｎｉｃ　 ）の商標名で提供される。この群はポリオキシプロピレングリコールを含む。One group of surfactant polymers useful in the present invention is BASF-Wyandotte Co. ASF - Wyandotte), Pluronic ) is offered under the trademark name. This group includes polyoxypropylene glycols.

もう一つは米国ＩＣＩ社からツイーン（Ｔｗｅｅｎ　）の商標名で提供される。The other one is provided by the American company ICI under the trade name Tween.

ツイーンは無水ソルビタンの部分的脂肪酸エステルのポリオキシエチレングリコ ール誘導体である。本発明の実地において最も有用なツイーンの中には、ソルビ タン−ラウレート、−ステアレート、−パルミテート、−オレエートのポリオキ シエチレングリコール誘導体がある。これらは分子量５００〜１０，０００を有 する。Tween is polyoxyethylene glyco, a partial fatty acid ester of anhydrous sorbitan. It is a derivative of alcohol. Among the most useful tweens in the practice of this invention are Solvi Tan-Laurate, -Stearate, -Palmitate, -Oleate Polyoxygen There are thiethylene glycol derivatives. These have a molecular weight of 500 to 10,000. do.

もう一つの有用なポリオキシアルキレングリコール誘導体群ハ、ユニオンカーバ イト社（Ｕｎｉｏｎ　Ｃａｒｂｉｄｅ　Ｃｏｒｐ、）からカーボワックス（Ｃａ ｒｂｏｗａｘ　）の商標名で提供される。Another useful group of polyoxyalkylene glycol derivatives is Union Carba. Carbowax (Ca) from Union Carbide Corp. It is provided under the trademark name rbowax.

既知の化合物アリルイソチオシアネー）（ＩＴＣ）をポリオキシエチレングリフ ールと、約２０℃〜６０℃の温度で約０．５〜３０時間反応させると、錯化合物 が生成することが発見された。ＩＴＣの、界面活性剤ポリマーに対する比は使用 する反応物質量に依存する。本発明の実施のためには、ＩＴＣの、界面活性剤ポ リマーに対する比は約１＝１から１：２０までである。反応のために好ましい溶 媒は水および炭素原子３箇まで含むアルカノールである。エタノールおよびイン プロパツールは好ましいアルカノールである。溶媒混合物を用いることができる 。The known compound allyl isothiocyanate (ITC) is a polyoxyethylene glyph. When reacted with a complex compound at a temperature of about 20°C to 60°C for about 0.5 to 30 hours, a complex compound is formed. was discovered to be generated. The ratio of ITC to surfactant polymer used depends on the amount of reactants used. For the practice of the present invention, the surfactant port of the ITC is The ratio to remer is approximately 1=1 to 1:20. The preferred solution for the reaction The medium is water and an alkanol containing up to 3 carbon atoms. ethanol and in Propertool is a preferred alkanol. Solvent mixtures can be used .

典型的には、錯化合物は、それが製造される際の溶媒混合物の形で利用される。Typically, the complex compound is utilized in the form of a solvent mixture in which it is prepared.

または溶媒混合物を他の担体と一緒にするかまたは混合してクリーム、ローショ ンその他を生成することができる。錯化合物を溶解して含み、この説明および請 求の目的からは薬用組成物とみなされるシャンプーを形成する溶媒混合物を利用 するのも便利である。or combine or mix the solvent mixture with other carriers to make creams, lotions, etc. can generate other information. Contains dissolved complex compounds and does not comply with this description and claims. The use of a solvent mixture to form a shampoo that is considered a medicinal composition for the purpose of It is also convenient to do so.

錯化合物を分離する必要はない。溶液中にそれが存在することは、最初の混合物 と最終混合物との間の、赤外線吸収曲線の形の変化によって容易に知ることがで きる。There is no need to separate complex compounds. Its presence in solution indicates that the initial mixture can be easily seen by the change in the shape of the infrared absorption curve between Wear.

錯化合物の生成は次の事実によっても確めることができる、すなわち錯化合物が 製造される際の溶媒と同じ溶媒にセロファンを通して拡散するＩＴＣの速度は、 錯化合物の拡散速度とは異なる。成る試料で測定した拡散常数は次のようである ： Ｋ　−ＩＴＣ＝　Ｚ６９　Ｘ　１０−２ｍ−’に−Ｉ　ＴＣ−ＴＷＥＥＮ−８０ −８，３６Ｘ　１０””ｍ１ｔｔ−’第一に記した拡散常数はＩＴＣのみのもの である。第二の拡散常数はツイーン８０とＩＴＣとの反応後に生成する錯化合物 のものである。ツイーン８０はポリオキシエチレン　ソルビタン　モノオレエー トである。The formation of a complex compound can also be confirmed by the following fact, namely that the complex compound The rate of diffusion of ITC through cellophane into the same solvent in which it is manufactured is: This is different from the diffusion rate of complex compounds. The diffusion constant measured for the sample consisting of : K -ITC=Z69X 10-2m-'-ITC-TWEEN-80 -8,36X　10””m1tt-’The first diffusion constant is for ITC only. It is. The second diffusion constant is the complex compound formed after the reaction between Tween 80 and ITC. belongs to. Tween 80 is polyoxyethylene sorbitan monooleate It is.

拡散速度はドウロプニ力（Ｄｒｏｂｎｉｃａ　）法によって測定した（　Ｄｒｏ ｂｎｉｃａ、　Ｋａｎｐｐｏｖａ　：　Ｃｈｅｍ、　Ｚｖｅｓｔｉ、　２７７９ ９（１９７３）　）。溶媒に溶かして調製した試験物質をセロファン透析セルに 入れ、そのセルを同じ溶媒の１０倍容量中につるす。定められた時間間隔でセル の外側の溶媒の一部をとシ、反応させて、拡散量の尺度となるチオグリコールを 生成せしめる。The diffusion rate was measured by the Drobnica method (Dro bnica, Kanppova: Chem, Zvesti, 2779 9 (1973)). The test substance prepared by dissolving it in a solvent is placed in a cellophane dialysis cell. and suspend the cell in 10 times the volume of the same solvent. cells at defined time intervals A part of the solvent on the outside of the cell is removed and reacted to form thioglycol, which is a measure of the amount of diffusion. Generate.

錯化合物は、液体、クリーム、ローション、皮膚軟化剤または局所適用のために 一般に用いられるその他の組成物を含む種々の組成物のどれにでも用いることが できる。有用な組成物は、組成物全重量を基にして約０．０１〜１０重量％の活 性成分を含む。組成物はその他の成分、たとえば防腐剤、殺菌剤または抗ふけ化 合物を含んでもよい。Complex compounds can be used as liquids, creams, lotions, emollients or for topical application. Can be used in any of a variety of compositions, including other commonly used compositions can. Useful compositions contain from about 0.01 to 10% active, based on the total weight of the composition. Contains sexual components. The composition may contain other ingredients such as preservatives, fungicides or anti-dandruff. It may also contain compounds.

錯化合物を含む組成物は、たとえば活性物質を含むシャンプーで髪を洗うことに より、或いはアルコール溶液で頭皮をマツサージすることによって、人の頭皮に 直接適用した場合、脱毛を防止する。これを確認するために行った研究で、実施 例７によってつくった試料を、脱毛の問題がある３０人に対して試験した。対照 として、錯化合物を含まない実施例７の担体を、やはシ脱毛に悩む別の３２人に 対して試験した。混合物を連続３０日日間上夕方に激しくすシ込むという方法で 適用した。製品の効果の決定は、新しく生えた毛髪の長さ、直径および周囲を光 顕微鏡によって測定するという方法で行われた。Compositions containing complex compounds can be used, for example, when washing hair with shampoos containing active substances. It can be applied to a person's scalp by rubbing the scalp with alcohol or by shaving the scalp with an alcohol solution. Prevents hair loss when applied directly. In a study conducted to confirm this, Samples made according to Example 7 were tested on 30 people with hair loss problems. contrast The carrier of Example 7, which does not contain a complex compound, was given to another 32 people suffering from hair loss. Tested against. By injecting the mixture vigorously in the evening for 30 consecutive days. Applied. The effectiveness of the product is determined by measuring the length, diameter and circumference of the newly grown hair. This was done by measuring using a microscope.

結果を次表に示す。The results are shown in the table below.

改善された　２２　７ 改善されなかった　８　２５ これらの試験中に、アレルギー反応または光感作反応はほとんどまたは全くない ことが判明した。Improved 22 7 No improvement 8 25 There are little or no allergic or photosensitization reactions during these tests. It has been found.

次の非限定的実施例は説明のためにのみ与えられる。The following non-limiting examples are given for illustrative purposes only.

実施例　１ ０．００８９７Ｍ　ＩＴＣを含む１．８：１　エタノール−水溶液１００ｗｔに 、０．００４５Ｍカーボワックスー６０００の溶液−を加え、その溶液を６時間 撹はんする。約４０℃の水浴でカナｏ　５　ム（Ｋａｎａｌｏｌｕｍ　）　５４ 　ｑ　、眼科用白色ワセリン（精製白色ワセリン）１０８ｇおよび白色ワセリン （ｐｅｔｒｏｌａｔｕｍ　）　７３８　ｇを軟化させる。クリーム基剤を均質化 し、上述のように調製した溶液を徐々にその中に分散させる。温かいクリームを 冷やしながら絶えず撹はんする。ＩＴＣ：ポリマー比は２：１である。組成物中 の錯化合物の濃度は重量で約２８である。Example 1 To 100wt of 1.8:1 ethanol-water solution containing 0.00897M ITC , a solution of 0.0045M carbowax-6000 was added, and the solution was incubated for 6 hours. Stir. Kanalolum 54 in a water bath at about 40℃ q, 108g of white petrolatum for ophthalmology (refined white petrolatum) and white petrolatum (petrolatum) 738 g is softened. Homogenize cream base and gradually disperse therein the solution prepared as described above. warm cream Stir constantly while cooling. The ITC:polymer ratio is 2:1. in the composition The concentration of the complex compound is about 28 by weight.

実施例　２ ０．００８９７Ｍ　Ｉ　Ｔ　Ｃを含む１．８　＝　１　エタ／　−ルー水溶１１ ００ｍ／Ｋ、０．００８９　Ｍ　カー　ｔ：　’７７　クス−６０００（７）溶 液を加え、実施例１の方法にしたがって行なう。ＩＴＣ：ポリマー比はｌ：１で ある。組成物中の錯化合物の濃度は約５．３重量％である。Example 2 1.8 containing 0.00897M ITC = 1 Eta/-Rue water soluble 11 00m/K, 0.0089M car t: '77 Kusu-6000 (7) melt The method of Example 1 is followed. ITC:polymer ratio is l:1 be. The concentration of complex compound in the composition is approximately 5.3% by weight.

実施例　３ ０．００８９７Ｍ　Ｉ　Ｔ　Ｃを含む１．８：１　エタノール−水溶液１００− に、０．００４５Ｍツイーン８０の溶液を加え、実施例１の方法を行って、工Ｔ Ｃ：ポリマーのモル比が２＝１である錯化合物をつくる。組成物中の錯化合物の 濃度は約０．７重量％である。Example 3 1.8:1 ethanol-water solution containing 0.00897M ITC 100- A solution of 0.0045M Tween 80 was added to the solution, and the method of Example 1 was carried out to obtain C: Create a complex compound in which the molar ratio of polymers is 2=1. of complex compounds in the composition The concentration is approximately 0.7% by weight.

実施例　４ ０．００８９７Ｍ　Ｉ　Ｔ　Ｃを含む１．８：１エタノール−水溶液１００−に 、０．１７９ツイ−７−８０の溶液を加え、実施例１の方法を行う。ＩＴＣ：ポ リマーのモル比は１：１９である。組成物中の錯化合物の濃度は約１０．７重量 ％である。Example 4 In a 1.8:1 ethanol-water solution containing 0.00897M ITC 100- , 0.179 Twi-7-80 and carry out the method of Example 1. ITC:Po The molar ratio of remers is 1:19. The concentration of complex compound in the composition is approximately 10.7 wt. %.

実施例　５ ０．００８９７Ｍ　Ｉ　Ｔ　Ｃを含む１．８：１エタノール−水溶液１００ｄＫ 、０．００８７９Ｍカーホ”７ｙりｘ−６０００ノ溶液を加え、生成した混合物 を４０℃で１５分分間上んする。Example 5 100 dK 1.8:1 ethanol-water solution containing 0.00897M ITC , and the resulting mixture Incubate at 40°C for 15 minutes.

反応混合物に、レゾルシン１ｏｇ、ヒマシ油１ｏｇ、イソプロピルアルコール４ ００９を加える。溶液を室温にまで冷やし、アルコール−水で１０００　ｄＫ希 釈する。To the reaction mixture, add 1 og of resorcinol, 1 og of castor oil, 4 oz of isopropyl alcohol. Add 009. Cool the solution to room temperature and dilute with alcohol-water to 1000 dK. Interpret.

ＩＴＣ＝ポリマーのモル比は１：１である。組成物中の錯化合物濃度は約１０％ である。The molar ratio of ITC=polymer is 1:1. The concentration of complex compound in the composition is approximately 10% It is.

実施例　６ ０．００４４９Ｍ　Ｉ　Ｔ　Ｃを含む１．８：１エタノール−水溶液１００ｄｌ Ｃ１０，００４９Ｍカーボｒｙ　ｙ　りｘ　−６０００ノ溶液ヲ加え、実施例５ の方法を行う。ＩＴＣ：ポリマーのモル比は１：１である。組成物中の錯化合物 濃度は灼５％である。Example 6 100 dl of 1.8:1 ethanol-water solution containing 0.00449M ITC Add a solution of C10,0049M carboxy-6000, Example 5 Do this method. The molar ratio of ITC:polymer is 1:1. Complex compounds in the composition The concentration is 5%.

実施例　７ ０．００８９７Ｍ　Ｉ　Ｔ　Ｃヲ含む７　ｋ　：ｌ）　−ルー　水溶液１００＋ ｄＫ、０．０１７９Ｍツイーン−８０の溶液を加え、それから実施例５に記載の 方法を行う。ＩＴＣ：ポリマーのモル比は１：１．９である。組成物中の錯化合 物濃度は約４．６％である。Example 7 0.00897M ITC containing 7k:l) - Roux aqueous solution 100+ dK, 0.0179M Tween-80 and then as described in Example 5. Do the method. The molar ratio of ITC:polymer is 1:1.9. Complex compounds in compositions The substance concentration is about 4.6%.

実施例　８ 年令１７−７７オの、脱毛のある２７人の患者（男性１０人２女性１７人）につ いて、２：１エタノール：水中の濃度０．２重量％の１：１．９　ＩＴＣ−ツイ ーン−８０錯化合物を用いて、脱毛の減少を評価した。Example 8 A study of 27 patients (10 men, 2 women, 17 women) with hair loss, aged 17-77 years. and 2:1 ethanol:1:1.9 ITC-Twi with a concentration of 0.2% by weight in water. The reduction in hair loss was evaluated using the Ane-80 complex compound.

使用法：夜歩量を頭皮に適用し、しづかにマツサージする。How to use: Apply nightly amount to the scalp and gently massage.

結果：患者および試験者によって評価が行われ、次のようにあられした二〇−変 化なし、１十−説毛がよシ少くなる、２十−説毛がずっと少くなる、３＋−それ 以上の脱毛なし。Results: The 20-change scores were evaluated by the patient and the examiner and were as follows: No change, 10-the theory will be much less, 20-the theory will be much less, 3+-it No further hair loss.

１）１０人（女性８人、男性２人）が混合物を１ケ月間用いた。彼等の中６人は ０，３人は１＋、１人は３＋であった。1) 10 people (8 women, 2 men) used the mixture for one month. Six of them 0.3 people were 1+, and 1 person was 3+.

２）５人（女性３人、男性２人）が混合物を２ケ月間用いた。彼等の中３人は０ ．１人は１＋および１人は３＋であった。2) Five people (3 women, 2 men) used the mixture for 2 months. 3 of them are 0 ．． One was 1+ and one was 3+.

３）４人（女性１人、男性３人）は混合物を３ケ月間用いた。彼等の中１人は０ ．１人は２＋、２人は３＋であ者は２＋であった。3) Four people (one woman, three men) used the mixture for three months. One of them is 0 ．． One person had a 2+, two had a 3+, and the other had a 2+.

５）３人（女性１人、男性２人）は混合物を５ケ月間用いた。彼等の中１人は２ ＋、２人は３＋であった。5) Three people (one woman, two men) used the mixture for 5 months. One of them is 2 +, 2 people got 3+.

６）４人（女性３人、男性１人）は混合物を６ケ月間用いた。彼等の中１人が０ ，１人が２＋、２人が３＋であった。6) Four people (3 women, 1 man) used the mixture for 6 months. One of them is 0 , 1 person was 2+ and 2 people were 3+.

不都合な反応は認められなかった。１人が１ひシひシする痛み’　（ｓｔｉｎｇ ｉｎｇ　）を訴えた。No adverse reactions were observed. The pain that pervades one person’ (sting) ing).

まとめ：１）１５人が混合物を１−２ケ月間使用した。Summary: 1) 15 people used the mixture for 1-2 months.

彼等の中９人が０．４人が１＋、２人が３＋であった。Nine of them had a score of 0.4 with a score of 1+ and two with a score of 3+.

２）１２人が混合物を３−６ケ月間使用した。彼等の中２人には変化がなく（Ｏ Ｌ４人には脱毛の中程度の減少があり（２＋）　、６人にはそれ以上の脱毛はお こらなかった（３＋）。2) 12 people used the mixture for 3-6 months. Two of them have not changed (O L4 had a moderate reduction in hair loss (2+) and 6 had no further hair loss. It didn't happen (3+).

結果を次表にまとめる。The results are summarized in the table below.

７７　１＋　７ｏ１＋　３６　０　５８２＋　７０３＋　４１　０３３　０　５ ０３＋　７０　３＋ ４５　０　３２０　７０　２＋ ６３３＋ 男　性 ３１０３５０２８３＋　３４３＋　４９３＋５０１＋　１７０３３２＋　２５２ ＋ ３３３＋ 国際調査報告 ＰＣＴ／［）５８６１０１３０４ Ａｔｔａｃｈｍｅｎｔ　ｔｏ　（ｓｅｃｏｎｄ　５ｈｅｅｔ）　Ｆｏｒｍ　ＰＣ Ｔ／工ＳＡ／２１０　Ｐａｒｔ　Ｉ工77 1 + 7o1 + 36 0 582 + 703 + 41 033 0 5 03+ 70 3+ 45 0 320 70 2+ 633+ male 310350283+ 343+ 493+501+ 170332+ 252 + 333+ international search report PCT/[)586101304 Attachment to (second 5 sheets) Form PC T/Engineering SA/210 Part I Eng.

Claims (23)

【特許請求の範囲】[Claims] １．人体頭皮の脱毛を予防するための薬用組成物であつて、アリルイソチオシア ネートと、分子量５００〜１０，０００を有するポリオキシアルキレングリコー ル界面活性剤ポリマーとの反応によつて生成する錯化合物を薬用に使用できる担 体と共に含み、アリルイソチオシアネートのポリマーに対する比は１：１〜１： ２０であり、ポリオキシアルキレン部分のアルキレン基は２〜３箇の炭素原子を 有する薬用組成物。1. A medicinal composition for preventing hair loss on the human scalp, the composition comprising: polyoxyalkylene glycol having a molecular weight of 500 to 10,000 A complex compound formed by reaction with a surfactant polymer can be used as a carrier for medicinal purposes. The ratio of allyl isothiocyanate to polymer is 1:1 to 1: 20, and the alkylene group of the polyoxyalkylene moiety has 2 to 3 carbon atoms. A medicinal composition comprising: ２．界面活性剤ポリマーがポリオキシエチレングリコールである請求の範囲第１ 項記載の薬用組成物。2. Claim 1, wherein the surfactant polymer is polyoxyethylene glycol. The medicinal composition described in . ３．界面活性剤ポリマーが無水ソルピトールの部分的脂肪酸エステルのポリオキ シエチレングリコール誘導体である請求の範囲第１項記載の薬用組成物。3. The surfactant polymer is a polyoxygenate partial fatty acid ester of anhydrous solpitol. The medicinal composition according to claim 1, which is a thiethylene glycol derivative. ４．界面活性剤ポリマーがソルピタンステアレートのポリオキシエチレングリコ ール誘導体である請求の範囲第１項記載の薬用組成物。4. Polyoxyethylene glycosurfactant polymer with sorpitan stearate 2. The medicinal composition according to claim 1, which is a roll derivative. ５．界面活性剤ポリマーがソルビタンラウレートのポリオキシエチレングリコー ル誘導体である請求の範囲第１項の薬用組成物。5. Polyoxyethylene glycol whose surfactant polymer is sorbitan laurate 2. The pharmaceutical composition according to claim 1, which is a compound based on alcohol. ６．界面活性剤ポリマーがソルビタンパルミテートのポリオキシエチレングリコ ール誘導体である請求の範囲第１項記載の薬用組成物。6. Polyoxyethylene glycosurfactant polymer is sorbitan palmitate 2. The medicinal composition according to claim 1, which is a roll derivative. ７．界面活性剤ポリマーがソルビタンオレエートのポリオキシエチレングリコー ル誘導体である請求の範囲第１項記載の薬用組成物。7. Polyoxyethylene glycol whose surfactant polymer is sorbitan oleate 2. The medicinal composition according to claim 1, which is a drug derivative. ８．界面活性剤ポリマーがポリオキシプロピレングリコールである請求の範囲第 １項記載の薬用組成物。8. Claim No. 1, wherein the surfactant polymer is polyoxypropylene glycol. The medicinal composition according to item 1. ９．アリルイソチオシアネートと分子量５００〜１０，０００を有するポリオキ シアルキレングリコール界面活性剤ポリマーとの反応産物てある錯化合物であつ て、アリルイソチオシアネートのポリマーに対する比は１：１〜１：２０で、ポ リオキシアルキレン部分のアルキレン基が２〜３箇の炭素原子を含む錯化合物。9. Allyl isothiocyanate and polyoxygenate having a molecular weight of 500 to 10,000 Sialkylene glycol is a complex compound that is a reaction product with surfactant polymers. The ratio of allyl isothiocyanate to polymer is 1:1 to 1:20, and A complex compound in which the alkylene group of the lyoxyalkylene moiety contains 2 to 3 carbon atoms. １０．界面活性剤ポりマーがポリオキシエチレングリコールである請求の範囲第 ９項記載の錯化合物。10. Claim No. 1, wherein the surfactant polymer is polyoxyethylene glycol. Complex compound according to item 9. １１．界面活性剤ポリマーが無水ソルピトールの部分的脂肪酸エステルのポリオ キシエチレングリコール誘導体である請求の範囲第９項記載の錯化合物。11. The surfactant polymer is polyol, a partial fatty acid ester of anhydrous solpitol. 10. The complex compound according to claim 9, which is a xyethylene glycol derivative. １２．界面活性剤ポリマーがソルピタンステアレートのポリオキシエチレングリ コール誘導体である請求の範囲第９項記載の錯化合物。12. The surfactant polymer is polyoxyethylene glycol with sorpitan stearate. 10. The complex compound according to claim 9, which is a call derivative. １３．界面活性剤ポリマーがソルビタンラウレートのポリオキシエチレングリコ ール誘導体である請求の範囲第９項記載の錯化合物。13. Polyoxyethylene glycosurfactant polymer is sorbitan laurate 10. The complex compound according to claim 9, which is a metal derivative. １４．界面活性剤ポリマーがソルビタンパルミテートのポリオキシエチレングリ コール誘導体である請求の範囲第９項記載の錯化合物。14. The surfactant polymer is polyoxyethylene glycol with sorbitan palmitate. 10. The complex compound according to claim 9, which is a call derivative. １５．界面活性剤ポリマーがソルビタンオレエートのポリオキシエチレングリコ ール誘導体である請求の範囲第９項記載の錯化合物。15. Polyoxyethylene glycosurfactant polymer is sorbitan oleate 10. The complex compound according to claim 9, which is a metal derivative. １６．界面活性剤ポリマーがポリオキシプロピレングリコールである請求の範囲 第９項記載の錯化合物。16. Claims where the surfactant polymer is polyoxypropylene glycol The complex compound according to item 9. １７．人体頭皮の脱毛を防止する方法であつて、アリルイソチオシアネートと分 子量５００〜１０，０００を有するポリオキシアルキレングリコール界面活性剤 ポリマーとの反応産物であつてアリルイソチオシアネートとポリマーとの比が１ ：１〜１：２０で、ポリオキシアルキレン部分のアルキレン基が２または３箇の 炭素原子を含むという錯化合物の脱毛防止に有効な量を頭皮に接触させることを 含んで成る方法。17. A method for preventing hair loss on the human scalp, which uses allyl isothiocyanate and Polyoxyalkylene glycol surfactant having a molecular weight of 500 to 10,000 A reaction product with a polymer in which the ratio of allyl isothiocyanate to the polymer is 1 :1 to 1:20, and the polyoxyalkylene moiety has 2 or 3 alkylene groups. Contacting the scalp with an effective amount of a complex compound containing carbon atoms to prevent hair loss. A method comprising. １８．界面活性剤ポリマーがポリオキシエチレングリコールである請求の範囲第 １７項記載の方法。18. Claim No. 1, wherein the surfactant polymer is polyoxyethylene glycol. The method according to item 17. １９．界面活性剤ポリマーが無水ソルピトールの脂肪酸部分エステルのポリオキ シエチレングリコール誘導体である請求の範囲第１７項記載の方法。19. The surfactant polymer is a polyoxylated fatty acid partial ester of anhydrous solpitol. 18. The method according to claim 17, which is a thiethylene glycol derivative. ２０．界面活性剤ポリマーがソルピタンステアレートのポリオキシエチレングリ コール誘導体である請求の範囲第１７項記載の方法。20. The surfactant polymer is polyoxyethylene glycol with sorpitan stearate. 18. The method according to claim 17, which is a call derivative. ２１．界面活性剤ポリマーがソルビタンラウレートのポリオキシエチレングリコ ール誘導体である請求の範囲第１７項の方法。21. Polyoxyethylene glycosurfactant polymer is sorbitan laurate 18. The method of claim 17, wherein the method is a polymer derivative. ２２．界面活性剤ポリマーがソルビタンパルミテートのポリオキシエチレングリ コール誘導体である請求の範囲第１７項記載の方法。22. The surfactant polymer is polyoxyethylene glycol with sorbitan palmitate. 18. The method according to claim 17, which is a call derivative. ２３．界面活性剤ポリマーがソルビタンオレエートのポリオキシエチレングリコ ール誘導体である請求の範囲第１７項記載の方法。23. Polyoxyethylene glycosurfactant polymer is sorbitan oleate 18. The method according to claim 17, wherein the method is a roll derivative.
JP61503578A 1985-06-20 1986-06-16 Medicinal hair loss prevention complex compounds and compositions Pending JPS63500517A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74696485A 1985-06-20 1985-06-20
US746964 1985-06-20

Publications (1)

Publication Number Publication Date
JPS63500517A true JPS63500517A (en) 1988-02-25

Family

ID=25003095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61503578A Pending JPS63500517A (en) 1985-06-20 1986-06-16 Medicinal hair loss prevention complex compounds and compositions

Country Status (3)

Country Link
EP (1) EP0229155A4 (en)
JP (1) JPS63500517A (en)
WO (1) WO1986007535A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008514A1 (en) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479903A (en) * 1982-08-23 1984-10-30 American Cyanamid Company Process for the preparation of N-allyl-O-alkyl thionocarbamates
US4482500A (en) * 1982-08-23 1984-11-13 American Cyanamid Company Process for the preparation of N-allyl-O-alkyl thionocarbamates
US4440783A (en) * 1983-02-24 1984-04-03 Bernard Weiss Composition for repelling animals from garbage and the like
US4524178A (en) * 1983-06-09 1985-06-18 The Dow Chemical Company Compositions of unsaturated polyesters or polyesteramides and efficient flexibilizers therefor

Also Published As

Publication number Publication date
EP0229155A1 (en) 1987-07-22
EP0229155A4 (en) 1991-03-13
WO1986007535A1 (en) 1986-12-31

Similar Documents

Publication Publication Date Title
JP2886688B2 (en) Novel compositions for foams, especially rectal foams, and foams obtained therefrom
US5519059A (en) Antifungal formulation
CA2060833C (en) Analgesic composition containing ibuprofen
US4857302A (en) Solubilized benzoyl peroxide and cosmetic solution including solubilized benzoyl peroxide
JPS6291237A (en) Novel translucent water-in-oil type emulsion
US4925666A (en) Solubilized benzoyl peroxide and cosmetic solution including solubilized benzoyl peroxide
JPH0131485B2 (en)
US4689217A (en) Amine and ammonium nitrogen containing polyvinyl alcohol polymers having improved lipophilic properties for use in skin conditioning, cosmetic and pharmaceutical formulations
WO2003051292A2 (en) Novel topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs
JP5488121B2 (en) Agents for promoting transdermal absorption and / or improving moisture retention, and cosmetics
EP1226822B1 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
JPS63500517A (en) Medicinal hair loss prevention complex compounds and compositions
JPS58500327A (en) Preparations that can be dissolved in water to produce approximately isotonic nitroglycerin solutions and nitroglycerin solutions of this kind
ATE147623T1 (en) MEDICINAL PREPARATION FOR PRODUCING A STABILIZED POWDER CONTAINING A COMBINATION OF ACETYLSALICYLIC ACID AND METOCLOPRAMIDE AS THE ACTIVE INGREDIENTS
JP2621976B2 (en) Anthralin-sterol complex, its production method and therapeutic / cosmetic use
JP3634112B2 (en) Topical skin preparation
JPH0725735A (en) Gargling agent
WO2001051530A1 (en) Lowly irritant high-molecular antimicrobial agent
Plein et al. A preliminary study of silicone oils as dermatological vehicles
JPH01301612A (en) Hair growth agent
Muktadir et al. Medicament Release from Ointment Bases: III. Ibuprofen: In Vitro Release and In-Vivo Absorption in Rabbits
JPH05229949A (en) Salicylic acid-blended preparation
EP0422466A1 (en) Endermic preparation of external application
JPH0354081B2 (en)
JP4182186B2 (en) Water-soluble polymer antibacterial agent